Cue Biopharma (CUE)vsInsmed Inc (INSM)
CUE
Cue Biopharma
$0.25
-4.24%
HEALTHCARE · Cap: $25.96M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 2108% more annual revenue ($606.42M vs $27.47M). INSM leads profitability with a -2.1% profit margin vs -96.9%. CUE earns a higher WallStSmart Score of 44/100 (D).
CUE
Hold44
out of 100
Grade: D
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -121.1% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CUE
The strongest argument for CUE centers on Price/Book. Revenue growth of 12.9% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CUE
The primary concerns for CUE are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CUE carries more volatility with a beta of 1.55 — expect wider price swings.
CUE is growing revenue faster at 12.9% — sustainability is the question.
CUE generates stronger free cash flow (-1M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
CUE scores higher overall (44/100 vs 39/100) and 12.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cue Biopharma
HEALTHCARE · BIOTECHNOLOGY · USA
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?